Open Access
2019 Robustifying trial-derived optimal treatment rules for a target population
Ying-Qi Zhao, Donglin Zeng, Catherine M. Tangen, Michael L. Leblanc
Electron. J. Statist. 13(1): 1717-1743 (2019). DOI: 10.1214/19-EJS1540

Abstract

Treatment rules based on individual patient characteristics that are easy to interpret and disseminate are important in clinical practice. Properly planned and conducted randomized clinical trials are used to construct individualized treatment rules. However, it is often a concern that trial participants lack representativeness, so it limits the applicability of the derived rules to a target population. In this work, we use data from a single trial study to propose a two-stage procedure to derive a robust and parsimonious rule to maximize the benefit in the target population. The procedure allows a wide range of possible covariate distributions in the target population, with minimal assumptions on the first two moments of the covariate distribution. The practical utility and favorable performance of the methodology are demonstrated using extensive simulations and a real data application.

Citation

Download Citation

Ying-Qi Zhao. Donglin Zeng. Catherine M. Tangen. Michael L. Leblanc. "Robustifying trial-derived optimal treatment rules for a target population." Electron. J. Statist. 13 (1) 1717 - 1743, 2019. https://doi.org/10.1214/19-EJS1540

Information

Received: 1 January 2018; Published: 2019
First available in Project Euclid: 30 April 2019

zbMATH: 07056162
MathSciNet: MR3944103
Digital Object Identifier: 10.1214/19-EJS1540

Keywords: Biased sample , ‎classification‎ , Individualized treatment rules , Minimax linear decision , Personalized medicine

Vol.13 • No. 1 • 2019
Back to Top